{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:41:42Z","timestamp":1785552102749,"version":"3.56.0"},"reference-count":22,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp;amp; Translational All"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) often coexists with other type 2 inflammatory diseases. Stapokibart, a humanized IgG4 monoclonal antibody targeting interleukin\u20104 receptor alpha subunit, showed high efficacy and favorable safety in a phase 3 trial. This post\u2010hoc analysis aimed to compare the efficacy and safety of stapokibart in AD patients with and without type 2 comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      During 16\u2010week double\u2010blind period, participants were randomly assigned to stapokibart 600 (loading dose)\u2010300\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0251) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0249) treatment every other week (Q2W). All patients received stapokibart 300\u00a0mg Q2W during subsequent 36\u2010week maintenance period. Patients with\u00a0\u2265\u00a01 of the following conditions were classified into comorbid subgroup: allergic rhinitis, asthma, food allergies, chronic urticaria, or chronic obstructive pulmonary disease. Post\u2010hoc outcomes included response rates of\u00a0\u2265\u00a075%\/90% improvement in Eczema Area and Severity Index score (EASI\u201075\/90), Investigator's Global Assessment score of 0 or 1 (IGA 0\/1) with \u2265\u00a02\u2010point reduction, and \u2265\u00a04\u2010point reduction in weekly average of daily peak pruritus numerical rating scale score (PP\u2010NRS4), and the percentage change from baseline in weekly average of daily PP\u2010NRS score. Treatment\u2010emergent adverse events (TEAEs) were also analyzed by subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety\u2010two patients (36.7%) in stapokibart group and 102 (41.0%) in placebo group had type 2 comorbidities. The demographic characteristics and baseline disease scores were generally comparable across four groups. At week 16, stapokibart demonstrated superior efficacy over placebo in patients with and without type 2 comorbidities. In patients with comorbidities, the response rates of EASI\u201075, IGA 0\/1, and PP\u2010NRS4 in stapokibart and placebo groups were 77.2% versus 26.5%, 55.4% versus 17.6%, and 43.5% versus 12.7%, respectively. In patients without comorbidities, these response rates were 61.0% versus 25.3%, 37.7% versus 15.1%, and 31.4% versus 11.0%, respectively (all\n                      <jats:italic>p<\/jats:italic>\n                      values\u00a0&lt;\u00a00.0001). All patients showed further improvements in efficacy outcomes during weeks 20\u201352. TEAEs occurred in 88.8% and 87.7% of comorbid and non\u2010comorbid patients over weeks 0\u201352. The incidence of conjunctivitis was 5.9% and 5.0%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Stapokibart was effective and safe in adults with moderate\u2010to\u2010severe AD both with and without type 2 comorbidities in both short\u2010term and long\u2010term treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT05265923<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/clt2.70121","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:07:22Z","timestamp":1763554042000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Stapokibart in Adults With Moderate\u2010to\u2010Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial"],"prefix":"10.1002","volume":"15","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Affiliated Hangzhou First People's Hospital School of Medicine Westlake University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Dermatology Hospital Southern Medical University  Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Ningbo No. 2 Hospital  Ningbo Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology Affiliated Hospital of Jiangsu University  Zhenjiang Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chongqing Traditional Chinese Medicine Hospital  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatovenereology West China Hospital of Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology Qilu Hospital of Shandong University  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wuxi No.2 People's Hospital (Jiangnan University Medical Center)  Wuxi Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Dermatology Second Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Central Hospital Affiliated to Shandong First Medical University  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chengdu Second People's Hospital  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Affiliated Hospital of Hainan Medical University  Haikou Hainan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology Beijing Friendship Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Third Xiangya Hospital of Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First People's Hospital of Lianyungang  Lianyungang Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Second Hospital of Jilin University  Changchun Jilin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases Institute of Dermatology Chinese Academy of Medical Sciences and Peking Union Medical College  Nanjing Jiangsu China"},{"name":"Key Laboratory of Basic and Translational Research on Immune\u2010Mediated Skin Diseases Chinese Academy of Medical Sciences  Nanjing Jiangsu China"},{"name":"Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Center for Plastic &amp; Reconstructive Surgery Department of Dermatology Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College)  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology The Second Xiangya Hospital of Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Affiliated Hospital of Fujian Medical University  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Keymed Biosciences (Chengdu) Co. Ltd  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chu","sequence":"additional","affiliation":[{"name":"Keymed Biosciences (Chengdu) Co. Ltd  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Keymed Biosciences (Chengdu) Co. Ltd  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)02519\u20104"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423\u2010025\u201001261\u20102"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.002"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408\u2010023\u201000603\u2010z"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19569"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.006"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.02.026"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.055"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000580\u20102"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1981813"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15928"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110721"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1447"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16368"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010025\u201002151\u20107"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.013"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.433"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.267"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18427"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.463"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001341\u20101"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:30:36Z","timestamp":1764239436000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/clt2.70121"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70121","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"e70121"}}